Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Single-Arm Phase 3 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Vedolizumab Intravenous in the Treatment of Pediatric Subjects With Active Chronic Pouchitis

NCT06443502 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT06443502
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06443502 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Single-Arm Phase 3 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Vedolizumab Intravenous in the Treatment of Pediatric Subjects With Active Chronic Pouchitis
Lead sponsor
Takeda
Phase
Phase 3
Overall status
Recruiting
Start date
November 19, 2024
Completion date
January 31, 2030
Enrollment
30 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

pouchitis